The Therapeutic Effect of Monotherapy and Combined Therapy for Androgen Blockade in Patients with Metastatic Prostate Cancer.
- Author:
Dae Gon KIM
1
;
Hyug Jun CHANG
;
Kyung Seop LEE
Author Information
1. Department of Urology, College of Medicine, Dongguk University, Gyeongju, Korea. ksleemd@dongguk.ac.kr
- Publication Type:Original Article
- Keywords:
Prostate cancer;
Metastasis;
Combined androgen blockade
- MeSH:
Castration;
Flutamide;
Humans;
Neoplasm Metastasis;
Prostate*;
Prostatic Neoplasms*;
Survival Rate
- From:Korean Journal of Urology
2003;44(1):12-16
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We evaluated the therapeutic effect of combined androgen blockade (CAB) compared with that of medical, or surgical, castration monotherapy, in the treatment of the metastatic prostate cancer. MATERIALS AND METHODS: Of 53 patients with metastatic prostate cancer, we compared the overall survival between CAB and monotherapy groups, using a Kaplan-Meier survival curve. We also compared the therapeutic effect of flutamide and bicalutamide in the CAB group. RESULTS: There were no differences in known prognostic factors between the CAB and monotherapy groups. The mean survival after treatment were 43 months in the CAB group, and 38 months in monotherapy group, with no significant difference (p=0.470). There were also no differences in the survival rates between the flutamide and bicalutamide groups (p=0.158). CONCLUSIONS: These results implicate that the CAB was no better than medical, or surgical, castration monotherapy in patients with metastatic prostate cancer, and that flutamide or bicalutamide, in CAB, resulted in similar efficacies and tolerabilities.
